Compare ProShares UltraPro Short QQQ ETF (SQQQ) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro Short QQQ ETF vs BIO-TECHNE Corp — how do they compare? ProShares UltraPro Short QQQ ETF trades at $32.64 (market cap $2.23B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 5.1× ProShares UltraPro Short QQQ ETF's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while ProShares UltraPro Short QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraPro Short QQQ ETF for 12 Days and BIO-TECHNE Corp for 63 Days on average.
| SQQQ | TECH | |
|---|---|---|
Market Cap | $2.23B | $11.36B |
Volume | 60,436,012 | 5,390,331 |
Sector | Leveraged / Inverse | Health |
52-Week High | $89.43 | $72.61 |
52-Week Low | $31.83 | $43.31 |
Typical Hold Time | 12 Days | 63 Days |
Enterprise Value | — | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SQQQ (ProShares UltraPro Short QQQ) trades at $32.08, up 0.79% today, as a 3x leveraged inverse ETF designed to profit from declines in the Nasdaq-100. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators suggest potential near-term oversold conditions. The ETF serves as a hedging tool against tech sector weakness, with recent news highlighting its strategic use alongside long QQQ positions.
Outlook remains tied to Nasdaq-100 performance; further tech sector declines could benefit SQQQ, but leveraged decay and volatility pose significant risks. Investors using SQQQ for hedging should monitor market sentiment and sector-specific catalysts. The ETF's structure makes it unsuitable for long-term holdings due to compounding effects in volatile markets.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
